Tigicon Capsule: Each capsule contains Fenofibrate BP 200 mg.
Fenofibrate is a fibric acid derivative. Fenofibrate is rapidly hydrolysed after oral ingestion into its pharmacologically active form fenofibric acid. Fenofibrate reduces total cholesterol, LDL cholesterol, apoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, Fenofibrate increases high density lipoprotein (HDL) and apo Al and apo All. The effects of Fenofibrats have seen in human hepatocyte cultures by the activation of peroxisome proliferator activated receptor a (PPARa). Fenofibrate also reduces serum uric acid levels in hyperuremic patients by increasing the urinary excretion of uric acid.
Tigicon is indicated for treatment of hyperlipidemia of Type IIa, IIb, III, IV and V in patients who have not responded adequately to diet & other appropriate measures.
Fenofibrate potentiates the action of oral anticoagulants. In patients receiving oral anticoagulant therapy the dose should be reduced by one third on starting Fanofibrates. Fenofibrates should not be used in combination with perhexiline maleate or with monoamine oxidase inhibitors.
Patients with liver disease or gallstone, renal impairment & hypersensitivity to Fenofibrate.
Nausea, anorexia, gastric pain, pruritus, urticaria, headache, dizziness, vertigo, fatigue.
Pregnancy: This drug should be used during pregnancy only if clearly needed.
Lactation: Because of the potential for adverse reactions in nursing infants from Tobramycin, a decision should be made whether to discontinue nursing the infant or discontinue the drug, taking into account the importance of the drug to the mother.
Special care should be needed In patients with renal disease. Discontinuation of the drug is necessary if creatinine kinase concentration increases significantly.